Plant Name: Ixora coccinea
Taxonomic Information:
Plant ID: NPO6876
Plant Latin Name: Ixora coccinea
Taxonomy Genus: Ixora
Taxonomy Family: Rubiaceae
Plant External Links:
NCBI TaxonomyDB:
43503
Plant-of-the-World-Online:
753844-1
Used in Medicines:
Country/Region:
Philippines; Indonesia; India; Vietnam; Thailand; NigeriaTraditional Medicine System:
Indian Folk; Ayurveda; SiddhaGeographical Distribution:
Australia; Honduras; Bangladesh; Mexico; El Salvador; Gambia; Philippines; Indonesia; India; Costa Rica; Cambodia; Nicaragua; Senegal; Vietnam; Colombia; Sri Lanka; Thailand; Nigeria; Belize; Fiji
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| TSHR; | |
| ALPL; RECQL; BLM; MTOR; HSD17B2; NOX4; | |
| TOP2A; | |
| FLT3; AURKA; | |
| CA12; CA9; CA7; CA4; | |
| RORC; | |
| NR1H4; | |
| TYR; | |
| MMP12; | |
| AHR; HIF1A; NFKB1; | |
| LMNA; THPO; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
| Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.595E-12 | 3.473E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.436E-11 | 7.007E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.273E-10 | 8.199E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.375E-09 | 1.181E-05 | CA12, CA4, CA7, CA9 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.922E-08 | 5.694E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, NOX4 |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.533E-08 | 6.169E-05 | ALPL, BLM, CYP1A1, CYP1B1, FLT3, NFKB1, NOX4, RORC |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 6.740E-08 | 7.865E-05 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 8.135E-08 | 8.435E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9, HSD17B2, NR1H4 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 2.690E-07 | 2.343E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 6.145E-07 | 4.460E-04 | CA12, CA4, CA7, CA9 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 7.367E-07 | 5.126E-04 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 7.533E-07 | 5.126E-04 | AHR, ALPL, AURKA, CYP1A1, CYP1A2, CYP1B1, FLT3, HIF1A, HSD17B2, LMNA, MTOR, RORC, SMN1, SMN2, THPO, TSHR, TYR |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.415E-06 | 2.403E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 5.863E-06 | 2.837E-03 | CYP1A1, CYP1A2, CYP1B1 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.863E-06 | 2.837E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0033554; cellular response to stress | 9.882E-06 | 4.138E-03 | AURKA, BLM, CA9, CYP1B1, HIF1A, LMNA, MTOR, NFKB1, NOX4, RECQL, TOP2A |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.396E-05 | 5.335E-03 | CYP1A1, CYP1A2 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.396E-05 | 5.335E-03 | CYP1A2, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0019216; regulation of lipid metabolic process | 1.714E-05 | 6.219E-03 | CYP1A1, FLT3, MTOR, NFKB1, NR1H4, RORC |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.958E-05 | 6.878E-03 | CYP1A1, CYP2C19, CYP2C9 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.325E-05 | 8.036E-03 | BLM, RECQL |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.440E-05 | 8.301E-03 | BLM, CA12, CA4, CA7, CA9, MMP12, NR1H4, RORC |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 2.758E-05 | 9.100E-03 | BLM, MTOR, NFKB1, NOX4, NR1H4, TSHR |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 9.655E-09 | 9.462E-07 | CA12, CA4, CA7, CA9 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.346E-07 | 6.597E-06 | CYP2C9, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.649E-06 | 5.388E-05 | CYP1A2, HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.165E-06 | 1.021E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 2.898E-05 | 4.734E-04 | CYP1A2, CYP1A1, CYP1B1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 5.692E-05 | 7.968E-04 | HSD17B2, CYP1A1, CYP1B1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.084E-05 | 2.124E-04 | CYP2C9, CYP1A2, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 8.437E-05 | 1.034E-03 | FLT3, NFKB1, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 1.367E-04 | 1.330E-03 | FLT3, HIF1A, MTOR |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.249E-04 | 1.330E-03 | CYP2C9, CYP1A2, CYP1A1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.493E-04 | 1.330E-03 | CYP2C9, CYP1A2, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 4.868E-04 | 3.975E-03 | HIF1A, NFKB1, MTOR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| C00-D49: Neoplasms | Breast cancer | C50 | FLT3; CA9; |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
| NA: NA | GIST | NA | FLT3; |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | FLT3; MTOR; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MTOR; |
| C00-D49: Neoplasms | CLL | NA | FLT3; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | TYR; |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR; |
| C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
| A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR; |
| C00-D49: Neoplasms | Melanoma | C43 | TYR; |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; MTOR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
| C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR; CA9; |
| NA: NA | Coronary artery restenosis | NA | MTOR; |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR; |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR; |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; FLT3; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; AURKA; FLT3; HIF1A; MTOR; CA9; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR; |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR; |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR; |
| I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
| C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; MTOR; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| NA: NA | HIV infections | NA | AHR; |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
| C00-D49: Neoplasms | AML | NA | FLT3; |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR; CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | AURKA; NFKB1; FLT3; HIF1A; MTOR; CA9; |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
